Can and should value-based pricing be applied to molecular diagnostics?

Personalized Medicine

Volumn 10, Issue 1, 2013, Pages 61-72

  Garau, Martina ^a   Towse, Adrian ^a   Garrison, Louis ^b   Housman, Laura ^c   Ossa, Diego ^d  

^a OFFICE OF HEALTH ECONOMICS   (United Kingdom)

^b UNIVERSITY OF WASHINGTON   (United States)

^c Market Access and Pricing   (United States)

^d NOVARTIS PHARMA AG   (Switzerland)

Author keywords

companion diagnostics; cost effectiveness; health technology assessment; molecular diagnostics; reimbursement; value based pricing

Indexed keywords

DRUG;

COST EFFECTIVENESS ANALYSIS; HEALTH CARE COST; HEALTH CARE POLICY; HUMAN; MOLECULAR DIAGNOSTICS; PATIENT COMPLIANCE; PATIENT INFORMATION; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; REVIEW;

EID: 84871428530     PISSN: 17410541     EISSN: 1744828X     Source Type: Journal    
DOI: 10.2217/pme.12.99     Document Type: Review

References (19)

1. Shah KK. Severity of illness and priority setting in healthcare: A review of the literature. Health Policy 93(2-3), 77-84 (2009
2. Garau M, Shah KK, Mason A, Wang Q, Towse A, Drummond M. Using QALYs in cancer: A review of the methodological limitations. Pharmacoeconomics 29(8), 673-685 (2011
3. Sussex J, Towse A, Devlin N. Operationalising value based pricing of medicines: A taxonomy of approaches. Pharmacoeconomics 31(1), doi:10.1007/s40273-012-0001-x (2013) (In Press
4. Garrison LP, Austin MJF. The economics of personalized medicine: A model of incentives for value creation and capture. Drug Information J. 41, 501-509 (2007
5. Danzon P, Towse A. The economics of gene therapy and of pharmacogenetics. Value Health 5(1), 5-13 (2002
6. Walker I, Newell H. Do molecularly targeted agents in oncology have reduced attrition rates? Nat. Rev. Drug Discov. 8, 15-16 (2009
7. Han P, Klein WM, Arora NK et al. Varieties of uncertainty in health care: A conceptual taxonomy. Med. Decis. Making 31(6), 828-838 (2011
8. Ash D, Patton J, Hershey J. Knowing for the sake of knowing: The value of prognostic information. Med. Decis. Making 10(1), 47-57 (1990
9. Neumann P Cohen JT, Hammitt JK et al. Willingness-To-pay for predictive tests with no immediate treatment implications: A survey of US residents. Health Econ. 21(3), 238-251 (2010
10. Ellsberg D. Risk, ambiguity, and the savage axioms. Quarterly J. Econ. (1961
11. Kenen R. The at-risk health status and technology: A diagnostic invitation and the gift of knowing. Soc. Sci. Med. 42, 1545-1553 (1996
12. Lee D, Neumann P, Rizzo J. Understanding the medical and nonmedical value of diagnostics testing. Value Health 13(2), 310-314 (2010
13. Claxton K, Posnett J. An economic approach to clinical trial design and research priority-setting. Health Econ. 5, 513-524 (1996
14. Aghion P, Tirole J. The management of innovation. Quarterly J. Econ. 109(4), 1185-1209 (1994
15. Drummond M, Griffiths A, Tarricone R. Economic evaluation for devices and drugs - same or different? Value Health 12(4), 402-406 (2009
16. Gustavsen G, Phillips K, Pothier K. The reimbursement landscape for novel diagnostics: Current limitations, real-world impact, and proposed solutions. Health Adv. (2010
17. Merlin T, Farah C, Schubert C, Mitchell A, Hiller JE, Ryan P. Assessing personalized medicines in Australia: A national framework for reviewing codependent technologies. Med. Decis. Making doi:10.1177/0272989X12452341 (2012) (Epub ahead of print
18. Housman L. Innovative tests for patient-Tailored treatments: Demonstrating value in the age of personalized medicine. Per. Med. 8(2), 183-189 (2011
19. Taylor R, Iglesias C. Assessing the clinical and cost-effectiveness of medical devices and drugs: Are they that different? Value Health 12(4), 404-406 (2009